Nanomedicines for back of the eye drug delivery, gene delivery, and imaging

Progress in Retinal and Eye Research

Volumn 36, Issue , 2013, Pages 172-198

  Kompella, Uday B ^a,b,c   Amrite, Aniruddha C ^d   Pacha Ravi, Rashmi ^a   Durazo, Shelley A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c The University of Colorado Denver   (United States)

^d THERAVANCE INC   (United States)

Author keywords

Controlled release; Drug delivery; Gene delivery; Imaging; Nanotechnology; Stimuli responsive delivery

Indexed keywords

ATENOLOL; BETAMETHASONE; BETAXOLOL; BEVACIZUMAB; BRIMONIDINE; BUDESONIDE; CARBOPLATIN; CELECOXIB; CHITOSAN; COPPER ZINC SUPEROXIDE DISMUTASE; DESLORELIN; DEXAMETHASONE SODIUM PHOSPHATE; DOXORUBICIN; GATIFLOXACIN; HUMAN SERUM ALBUMIN; MELANIN; METHACRYLIC ACID; METOPROLOL; NADOLOL; PACLITAXEL; PINDOLOL; POLYAMIDOAMINE; POLYCAPROLACTONE; POLYMETHACRYLIC ACID; PROPRANOLOL; SOTALOL; TIMOLOL; TIMOLOL MALEATE;

BIOACCUMULATION; CATTLE; CELL SURFACE; CHOROID; CLEARANCE; CONCENTRATION (PARAMETERS); CONTROLLED DRUG RELEASE; CORNEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISPOSITION; DRUG HALF LIFE; DRUG RELEASE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TRANSPORT; EYE TOXICITY; GENE TARGETING; GENETIC TRANSFECTION; HEAT; HUMAN; IMPLANT; INTERNALIZATION; INTRAOCULAR DRUG ADMINISTRATION; LENS; LIGHT; LIPOPHILICITY; LONG TERM EXPOSURE; MICELLE; MICRONEEDLE; NANOFABRICATION; NANOIMAGING; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PERIOCULAR DRUG ADMINISTRATION; PH; PIG FARMING; PIGMENTATION; PREDICTION; PRIORITY JOURNAL; RABBIT; RETINA; REVIEW; SCLERA; SPECIES DIFFERENCE; SUSTAINED DRUG RELEASE; THICKNESS; ULTRASOUND; VELOCITY; VISUAL PROSTHESIS; VITREOUS BODY;

CONTROLLED RELEASE; DRUG DELIVERY; GENE DELIVERY; IMAGING; NANOTECHNOLOGY; STIMULI RESPONSIVE DELIVERY;

ANIMALS; DRUG DELIVERY SYSTEMS; EYE DISEASES; GENE TRANSFER TECHNIQUES; HUMANS; MICRO-ELECTRICAL-MECHANICAL SYSTEMS; NANOMEDICINE; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; POSTERIOR EYE SEGMENT;

EID: 84883219531     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2013.04.001     Document Type: Review

References (197)

1. Acheampong A.A., Shackleton M., John B., Burke J., Wheeler L., Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos. 2002, 30:421-429.
2. Acheampong A.A., Small D., Baumgarten V., Welty D., Tang-Liu D. Formulation effects on ocular absorption of brimonidine in rabbit eyes. J.Ocul. Pharmacol. Ther. 2002, 18:325-337.
3. Akagi T., Kim H., Akashi M. pH-dependent disruption of erythrocyte membrane by amphiphilic poly(amino acid) nanoparticles. J.Biomater. Sci. Polym. Ed. 2010, 21:315-328.
4. Alghadyan A.A., Peyman G.A., Khoobehi B., Milner S., Liu K.R. Liposome-bound cyclosporine: clearance after intravitreal injection. Int. Ophthalmol. 1988, 12:109-112.
5. Amaral J., Fariss R.N., Campos M.M., Robison W.G., Kim H., Lutz R., Becerra S.P. Transscleral-RPE permeability of PEDF and ovalbumin proteins: implications for subconjunctival protein delivery. Invest. Ophthalmol. Vis. Sci. 2005, 46:4383-4392.
6. Ambati J., Canakis C.S., Miller J.W., Gragoudas E.S., Edwards A., Weissgold D.J., Kim I., Delori F.C., Adamis A.P. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 2000, 41:1181-1185.
7. Amrite A.C., Ayalasomayajula S.P., Cheruvu N.P., Kompella U.B. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 2006, 47:1149-1160.
8. Amrite A.C., Edelhauser H.F., Kompella U.B. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest. Ophthalmol. Vis. Sci. 2008, 49:320-332.
9. Amrite A.C., Edelhauser H.F., Singh S.R., Kompella U.B. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol. Vis. 2008, 14:150-160.
10. Amrite A.C., Kompella U.B. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J.Pharm. Pharmacol. 2005, 57:1555-1563.
11. Amrite A.C., Kompella U.B. Nanoparticles for ocular drug delivery. Nanoparticle Technology for Drug Delivey 2006, 319-360. Informa Healthcare. R.B. Gupta, U.B. Kompella (Eds.).
12. Aoyagi S., Hayato I., Yuichi I., Mitsuo F.H.O. Laser fabrication of high aspect ratio thin holes on biodegradable polymer and its application to a microneedle. Sens Actuators A Phys. 2007, 139:293-302.
13. Ashok B., Arleth L., Hjelm R.P., Rubinstein I., Onyuksel H. Invitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J.Pharm. Sci. 2004, 93:2476-2487.
14. Aukunuru J.V., Ayalasomayajula S.P., Kompella U.B. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J.Pharm. Pharmacol. 2003, 55:1199-1206.
15. Aukunuru J.V., Kompella U.B. Invitro delivery of nano- and micro-particles to human retinal pigment epithelial (ARPE-19) cells. Drug Deliv. Technol. 2002, 2:50-57.
16. Ayalasomayajula S.P., Kompella U.B. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur. J. Pharmacol. 2003, 458:283-289.
17. Ayalasomayajula S.P., Kompella U.B. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm. Res. 2004, 21:1797-1804.
18. Ayalasomayajula S.P., Kompella U.B. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur. J. Pharmacol. 2005, 511:191-198.
19. Bernstein H.N. Chloroquine ocular toxicity. Surv. Ophthalmol. 1967, 12:415-447.
20. Bill A. Movement of Albumin and Dextran through the Sclera. Arch. Ophthalmol. 1965, 74:248-252.
21. Boddu S.H., Jwala J., Chowdhury M.R., Mitra A.K. Invitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug. J.Ocul. Pharmacol. Ther. The Off. J. Assoc. Ocul. Pharmacol. Ther. 2010, 26:459-468.
22. Carrasquillo K.G., Ricker J.A., Rigas I.K., Miller J.W., Gragoudas E.S., Adamis A.P. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest. Ophthalmol. Vis. Sci. 2003, 44:290-299.
23. Ceulemans J., Ludwig A. Optimisation of carbomer viscous eye drops: an invitro experimental design approach using rheological techniques. Eur. J. Pharm. Biophar.: Off. J. Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik e.V 2002, 54:41-50.
24. Cheruvu N.P., Amrite A.C., Kompella U.B. Effect of eye pigmentation on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci. 2008, 49:333-341.
25. Cheruvu N.P., Amrite A.C., Kompella U.B. Effect of diabetes on transscleral delivery of celecoxib. Pharm. Res. 2009, 26:404-414.
26. Cheruvu N.P., Kompella U.B. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest. Ophthalmol. Vis. Sci. 2006, 47:4513-4522.
27. Cho Y.K., Uehara H., Young J.R., Tyagi P., Kompella U.B., Zhang X., Luo L., Singh N., Archer B., Ambati B.K. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest. Ophthalmol. Vis. Sci. 2012, 53:2328-2336.
28. Chopra P., Hao J., Li S.K. Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera. J.Control Release 2012, 160:96-104.
29. Christie J.G., Kompella U.B. Ophthalmic light sensitive nanocarrier systems. Drug Discov. Today 2008, 13:124-134.
30. Ciechanover A., Schwartz A.L., Lodish H.F. Sorting and recycling of cell surface receptors and endocytosed ligands: the asialoglycoprotein and transferrin receptors. J.Cell. Biochem. 1983, 23:107-130.
31. Conley S.M., Naash M.I. Nanoparticles for retinal gene therapy. Prog. Retin. Eye Res. 2010, 29:376-397.
32. Cruysberg L.P., Nuijts R.M., Geroski D.H., Koole L.H., Hendrikse F., Edelhauser H.F. Invitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system. J.Ocul. Pharmacol. Ther. The Off. J. Assoc. Ocul. Pharmacol. Ther. 2002, 18:559-569.
33. Cunha-Vaz J. Diabetic macular edema. Eur. J. Ophthalmol. 1998, 8:127-130.
34. Davis S.P., Martanto W., Allen M.G., Prausnitz M.R. Hollow metal microneedles for insulin delivery to diabetic rats. IEEE Trans. Biomed. Eng. 2005, 52:909-915.
35. De Campos A.M., Sanchez A., Alonso M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 2001, 224:159-168.
36. De Juan E.J., Alster Y., Chamow S.M., Farinas K.C., Gifford H.S., MacFarlane K.A., Reich C.J., Barrett M., Campbell R.E., George R., Sutton D. Posterior Segment Drug Delivery, A61F 9/00; A61K 39/395; A61P 27/02; A61K 31/5575; A61K 31/58; A61F 2/14; B23P 17/04 Ed 2010, ForSight Labs, LLC, United States.
37. Diebold Y., Calonge M. Applications of nanoparticles in ophthalmology. Prog. Retin. Eye Res. 2010, 29:596-609.
38. Do carmo A., Ramos P., Reis A., Proenca R., Cunha-vaz J.G. Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp. Eye Res. 1998, 67:569-575.
39. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2007, 2:469-478.
40. Donnelly R.F., Morrow D.I., Singh T.R., Migalska K., McCarron P.A., O'Mahony C., Woolfson A.D. Processing difficulties and instability of carbohydrate microneedle arrays. Drug Dev. Ind. Pharm. 2009, 35:1242-1254.
41. Durairaj C., Kadam R.S., Chandler J.W., Hutcherson S.L., Kompella U.B. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest. Ophthalmol. Vis. Sci. 2010, 51:5804-5816.
42. Durairaj C., Kim S.J., Edelhauser H.F., Shah J.C., Kompella U.B. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest. Ophthalmol. Vis. Sci. 2009, 50:4887-4897.
43. Durazo S.A., Kompella U.B. Functionalized Nanosystems for Targeted Mitochondrial Delivery 2011, Mitochondrion.
44. Durrani A.M., Farr S.J., Kellaway I.W. Precorneal clearance of mucoadhesive microspheres from the rabbit eye. J.Pharm. Pharmacol. 1995, 47:581-584.
45. Duvvuri S., Janoria K.G., Pal D., Mitra A.K. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d, L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis. J.Ocul. Pharmacol. Ther. The Off. J. Assoc. Ocul. Pharmacol. Ther. 2007, 23:264-274.
46. Edelhauser H.F., Maren T.H. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch. Ophthalmol. 1988, 106:1110-1115.
47. Einmahl S., Savoldelli M., D'Hermies F., Tabatabay C., Gurny R., Behar-Cohen F. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest. Ophthalmol. Vis. Sci. 2002, 43:1533-1539.
48. El-Remessy A.B., Behzadian M.A., Abou-Mohamed G., Franklin T., Caldwell R.W., Caldwell R.B. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am. J. Pathol. 2003, 162:1995-2004.
49. Enriquez de Salamanca A., Diebold Y., Calonge M., Garcia-Vazquez C., Callejo S., Vila A., Alonso M.J. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and invivo tolerance. Invest. Ophthalmol. Vis. Sci. 2006, 47:1416-1425.
50. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
51. Fujii Y., Kachi S., Ito A., Kawasumi T., Honda H., Terasaki H. Transfer of gene to human retinal pigment epithelial cells using magnetite cationic liposomes. Br. J. Ophthalmol. 2010, 94:1074-1077.
52. Fujisawa T., Miyai H., Hironaka K., Tsukamoto T., Tahara K., Tozuka Y., Ito M., Takeuchi H. Liposomal diclofenac eye drop formulations targeting the retina: formulation stability improvement using surface modification of liposomes. Int. J. Pharmaceutics 2012, 436:564-567.
53. Furrer E., Berdugo M., Stella C., Behar-Cohen F., Gurny R., Feige U., Lichtlen P., Urech D.M. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest. Ophthalmol. Vis. Sci. 2009, 50:771-778.
54. Geze A., Chau L.T., Choisnard L., Mathieu J.P., Marti-Batlle D., Riou L., Putaux J.L., Wouessidjewe D. Biodistribution of intravenously administered amphiphilic beta-cyclodextrin nanospheres. Int. J. Pharmaceutics 2007, 344:135-142.
55. Ghate D., Brooks W., McCarey B.E., Edelhauser H.F. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest. Ophthalmol. Vis. Sci. 2007, 48:2230-2237.
56. Gilger B.C., Salmon J.H., Wilkie D.A., Cruysberg L.P., Kim J., Hayat M., Kim H., Kim S., Yuan P., Lee S.S., Harrington S.M., Murray P.R., Edelhauser H.F., Csaky K.G., Robinson M.R. Anovel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest. Ophthalmol. Vis. Sci. 2006, 47:2596-2605.
57. Gilger B.C., Wilkie D.A., Clode A.B., McMullen R.J., Utter M.E., Komaromy A.M., Brooks D.E., Salmon J.H. Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. Vet. Ophthalmol. 2010, 13:294-300.
58. Gong X., Peng S., Wen W., Sheng P., Li W. Design and fabrication of magnetically functionalized core/shell microspheres for smart drug delivery. Adv. Funct. Mater. 2009, 19:292-297.
59. Grayson A.C.R., Shawgo R.S., Johnson A.M., Flynn N.T., Yawen L., Cima M.J., Langer R. ABioMEMS review: MEMS technology for physiologically integrated devices. Proc. IEEE 2004, 92:6-21.
60. Gupta R.B., Kompella U.B. Nanoparticle Technology for Drug Delivery 2006, Taylor & Francis Group, New York.
61. Hashmi S., Ling P., Hashmi G., Reed M., Gaugler R., Trimmer W. Genetic transformation of nematodes using arrays of micromechanical piercing structures. Biotechniques 1995, 19:766-770.
62. Hassan E.E., Gallo J.M. Asimple rheological method for the invitro assessment of mucin-polymer bioadhesive bond strength. Pharm. Res. 1990, 7:491-495.
63. Henry S., McAllister D.V., Allen M.G., Prausnitz M.R. Microfabricated microneedles: a novel approach to transdermal drug delivery. J.Pharm. Sci. 1998, 87:922-925.
64. Holden C.A., Tyagi P., Thakur A., Kadam R., Jadhav G., Kompella U.B., Yang H. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine 2012, 8:776-783.
65. Honda M., Asai T., Umemoto T., Araki Y., Oku N., Tanaka M. Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416. Arch. Ophthalmol. 2012, 129:317-321.
66. Horgan N., Shields C.L., Mashayekhi A., Salazar P.F., Materin M.A., O'Regan M., Shields J.A. Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial. Ophthalmology 2009, 116:1383-1390.
67. Hornof M., Weyenberg W., Ludwig A., Bernkop-Schnurch A. Mucoadhesive ocular insert based on thiolated poly(acrylic acid): development and invivo evaluation in humans. J.Control Release 2003, 89:419-428.
68. Howard D.B., Powers K., Wang Y., Harvey B.K. Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia invitro. Virology 2008, 372:24-34.
69. Iezzi R., Guru B.R., Glybina I.V., Mishra M.K., Kennedy A., Kannan R.M. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012, 33:979-988.
70. Ito Y., Hagiwara E., Saeki A., Sugioka N., Takada K. Feasibility of microneedles for percutaneous absorption of insulin. Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci. 2006, 29:82-88.
71. Jani P.D., Singh N., Jenkins C., Raghava S., Mo Y., Amin S., Kompella U.B., Ambati B.K. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest. Ophthalmol. Vis. Sci. 2007, 48:2030-2036.
72. Jiang J., Gill H.S., Ghate D., McCarey B.E., Patel S.R., Edelhauser H.F., Prausnitz M.R. Coated microneedles for drug delivery to the eye. Invest. Ophthalmol. Vis. Sci. 2007, 48:4038-4043.
73. Jiang J., Moore J.S., Edelhauser H.F., Prausnitz M.R. Intrascleral drug delivery to the eye using hollow microneedles. Pharm. Res. 2009, 26:395-403.
74. Jin J., Zhou K.K., Park K., Hu Y., Xu X., Zheng Z., Tyagi P., Kompella U.B., Ma J.X. Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. Invest. Ophthalmol. Vis. Sci. 2011, 52:6230-6237.
75. Jockovich M.E., Murray T.G., Escalona-Benz E., Hernandez E., Feuer W. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest. Ophthalmol. Vis. Sci. 2006, 47:1264-1268.
76. Jonas J.B., Spandau U.H., Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond.) 2008, 22:590-591.
77. Kadam R.S., Cheruvu N.P., Edelhauser H.F., Kompella U.B. Sclera-choroid-RPE transport of eight beta-blockers in human, bovine, porcine, rabbit, and rat models. Invest. Ophthalmol. Vis. Sci. 2011, 52:5387-5399.
78. Kadam R.S., Tyagi P., Edelhauser H.F., Kompella U.B. Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int. J. Pharmaceutics 2012, 434:140-147.
79. Kang S.J., Durairaj C., Kompella U.B., O'Brien J.M., Grossniklaus H.E. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch. Ophthalmol. 2009, 127:1043-1047.
80. Kato A., Kimura H., Okabe K., Okabe J., Kunou N., Ogura Y. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest. Ophthalmol. Vis. Sci. 2004, 45:238-244.
81. Kaushik S., Hord A.H., Denson D.D., McAllister D.V., Smitra S., Allen M.G., Prausnitz M.R. Lack of pain associated with microfabricated microneedles. Anesth. Analg. 2001, 92:502-504.
82. Khraiche M.L., Lo Y., Wang D., Cauwenberghs G., Freeman W., Silva G.A. Ultra-high photosensitivity silicon nanophotonics for retinal prosthesis: electrical characteristics. Eng. Med. Biol. Soc. 2011, 2933-2936.
83. Kiang T., Bright C., Cheung C.Y., Stayton P.S., Hoffman A.S., Leong K.W. Formulation of chitosan-DNA nanoparticles with poly(propyl acrylic acid) enhances gene expression. J.Biomater. Sci. Polym. Ed. 2004, 15:1405-1421.
84. Kim H., Csaky K.G., Gilger B.C., Dunn J.P., Lee S.S., Tremblay M., de Monasterio F., Tansey G., Yuan P., Bungay P.M., Lutz R.J., Robinson M.R. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest. Ophthalmol. Vis. Sci. 2005, 46:655-662.
85. Kim H., Robinson M.R., Lizak M.J., Tansey G., Lutz R.J., Yuan P., Wang N.S., Csaky K.G. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest. Ophthalmol. Vis. Sci. 2004, 45:2722-2731.
86. Kim T.W., Lindsey J.D., Aihara M., Anthony T.L., Weinreb R.N. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest. Ophthalmol. Vis. Sci. 2002, 43:1809-1816.
87. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J., Yamasaki S., Itaya M., Pan Y., Appukuttan B., Gibbs D., Yang Z., Kariko K., Ambati B.K., Wilgus T.A., DiPietro L.A., Sakurai E., Zhang K., Smith J.R., Taylor E.W., Ambati J. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452:591-597.
88. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-237.
89. Kolli C.S., Banga A.K. Characterization of solid maltose microneedles and their use for transdermal delivery. Pharm. Res. 2008, 25:104-113.
90. Kompella U.B., Bandi N., Ayalasomayajula S.P. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. 2003, 44:1192-1201.
91. Kompella U.B., Kadam R.S., Lee V.H. Recent advances in ophthalmic drug delivery. Ther. Deliv. 2010, 1:435-456.
92. Kompella U.B., Sundaram S., Raghava S., Escobar E.R. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine exvivo eye model. Mol. Vis. 2006, 12:1185-1198.
93. Kompella U.B., Upadhyay A. Trasferrin-functionalized PLGA Nanopartilces Sustain Diclofenac Delivery to Choroid-rpe 2012, The Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL.
94. Koushik K., Bandi N., Sundaram S., Kompella U.B. Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharm. Res. 2004, 21:1034-1046.
95. Kragh-Hansen U., Chuang V.T., Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 2002, 25:695-704.
96. Kwon G.S. Polymeric micelles for delivery of poorly water-soluble compounds. Crit. Rev. Ther. Drug Carrier Syst. 2003, 20:357-403.
97. Ladas I.D., Karagiannis D.A., Rouvas A.A., Kotsolis A.I., Liotsou A., Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009, 29:313-318.
98. Leblanc B., Jezequel S., Davies T., Hanton G., Taradach C. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul. Toxicol. Pharmacol. 1998, 28:124-132.
99. Lee J.W., Park J.H., Prausnitz M.R. Dissolving microneedles for transdermal drug delivery. Biomaterials 2008, 29:2113-2124.
100. Lee T.W., Robinson J.R. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection. J.Ocul. Pharmacol. Ther. The Off. J. Assoc. Ocul. Pharmacol. Ther. 2004, 20:43-53.
101. Lehr C.M., Bouwstra J.A., Kok W., De Boer A.G., Tukker J.J., Verhoef J.C., Breimer D.D., Junginger H.E. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat. J.Pharm. Pharmacol. 1992, 44:402-407.
102. Lehr C.M., Lee Y.H., Lee V.H. Improved ocular penetration of gentamicin by mucoadhesive polymer polycarbophil in the pigmented rabbit. Invest. Ophthalmol. Vis. Sci. 1994, 35:2809-2814.
103. Liu H., Meagher C.K., Moore C.P., Phillips T.E. Mcells in the follicle-associated epithelium of the rabbit conjunctiva preferentially bind and translocate latex beads. Invest. Ophthalmol. Vis. Sci. 2005, 46:4217-4223.
104. Lloyd A.W., Faragher R.G., Denyer S.P. Ocular biomaterials and implants. Biomaterials 2001, 22:769-785.
105. Lo R., Li P.Y., Saati S., Agrawal R.N., Humayun M.S., Meng E. Apassive MEMS drug delivery pump for treatment of ocular diseases. Biomed. Microdevices 2009, 11:959-970.
106. Luo L., Zhang X., Hirano Y., Tyagi P., Barabás P., Uehara H., Miya T.R., Singh N., Archer B., Qazi Y., Jackman K., Das S.K., Olsen T., Chennamaneni S.R., Stagg B.C., Ahmed F., Emerson L., Zygmunt K., Whitaker R., Mamalis C., Huang W., Gao G., Srinivas S.P., Krizaj D., Baffi J., Ambati J., Kompella U.B., Ambati B.K. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano 2013, 7:3264-3275.
107. Mac Gabhann F., Demetriades A.M., Deering T., Packer J.D., Shah S.M., Duh E., Campochiaro P.A., Popel A.S. Protein transport to choroid and retina following periocular injection: theoretical and experimental study. Ann. Biomed. Eng. 2007, 35:615-630.
108. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 1989, 6:193-210.
109. Mars U., Larsson B.S. Pheomelanin as a binding site for drugs and chemicals. Pigment Cell Res./Sponsored by Eur. Soc. Pigment Cell Res. Int. Pigment Cell Soc. 1999, 12:266-274.
110. Martin N.E., Kim J.W., Abramson D.H. Fibrin sealant for retinoblastoma: where are we?. J.Ocul. Pharmacol. Ther. The Off. J. Assoc. Ocul. Pharmacol. Ther. 2008, 24:433-438.
111. Matsumura Y., Maeda H. Anew concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
112. Maurice D.M. Drug delivery to the posterior segment from drops. Surv. Ophthalmol. 2002, 47(Suppl. 1):S41-S52.
113. Maurice D.M., Polgar J. Diffusion across the sclera. Exp. Eye Res. 1977, 25:577-582.
114. Mayo A.S., Ambati B.K., Kompella U.B. Gene delivery nanoparticles fabricated by supercritical fluid extraction of emulsions. Int. J. Pharmaceutics 2010, 387:278-285.
115. McAllister D.V., Wang P.M., Davis S.P., Park J.H., Canatella P.J., Allen M.G., Prausnitz M.R. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13755-13760.
116. McAllister K., Sazani P., Adam M., Cho M.J., Rubinstein M., Samulski R.J., DeSimone J.M. Polymeric nanogels produced via inverse microemulsion polymerization as potential gene and antisense delivery agents. J.Am. Chem. Soc. 2002, 124:15198-15207.
117. McNeil S.E. Nanotechnology for the biologist. J.Leukoc. Biol. 2005, 78:585-594.
118. Meagher C.K., Liu H., Moore C.P., Phillips T.E. Conjunctival M cells selectively bind and translocate Maackia amurensis leukoagglutinin. Exp. Eye Res. 2005, 80:545-553.
119. Medina C., Santos-Martinez M.J., Radomski A., Corrigan O.I., Radomski M.W. Nanoparticles: pharmacological and toxicological significance. Br. J. Pharmacol. 2007, 150:552-558.
120. Meng J., Sturgis T.F., Youan B.B. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci. 2011, 44:57-67.
121. Misra G.P., Singh R.S., Aleman T.S., Jacobson S.G., Gardner T.W., Lowe T.L. Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. Biomaterials 2009, 30:6541-6547.
122. Mitra M., Misra R., Harilal A., Sahoo S.K., Krishnakumar S. Enhanced invitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mol. Vis. 2011, 17:2724-2737.
123. Miyano T., Tobinaga Y., Kanno T., Matsuzaki Y., Takeda H., Wakui M., Hanada K. Sugar micro needles as transdermic drug delivery system. Biomed. Microdevices 2005, 7:185-188.
124. Mo Y., Barnett M.E., Takemoto D., Davidson H., Kompella U.B. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol. Vis. 2007, 13:746-757.
125. Moghimi S.M., Porter C.J., Muir I.S., Illum L., Davis S.S. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem. Biophys. Res. Commun. 1991, 177:861-866.
126. Moon S.J., Lee S.S., Lee H.S., Kwon T.H. Fabrication of microneedle array using LIGA and hot embossing pocess. Microsyst Technol. Micro Nanosyst Informat Storage Proc. Syst. 2005, 11:311-318.
127. Murray T.G., Cicciarelli N., O'Brien J.M., Hernandez E., Mueller R.L., Smith B.J., Feuer W. Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Arch. Ophthalmol. 1997, 115:1286-1290.
128. Okabe K., Kimura H., Okabe J., Ogura Y. Ocular tissue distribution of betamethasone after anterior-episcleral, posterior-episcleral, and anterior-intrascleral placement of nonbiodegradable implants. Retina 2007, 27:770-777.
129. Olsen T.W., Feng X., Wabner K., Conston S.R., Sierra D.H., Folden D.V., Smith M.E., Cameron J.D. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am. J. Ophthalmol. 2006, 142:777-787.
130. Olsen T.W., Feng X., Wabner K., Csaky K., Pambuccian S., Cameron J.D. Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model. Invest. Ophthalmol. Vis. Sci. 2011, 52:4749-4756.
131. Ottiger M., Thiel M.A., Feige U., Lichtlen P., Urech D.M. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest. Ophthalmol. Vis. Sci. 2009, 50:779-786.
132. Ovsianikov A., Schlie S., Ngezahayo A., Haverich A., Chichkov B.N. Two-photon polymerization technique for microfabrication of CAD-designed 3D scaffolds from commercially available photosensitive materials. J.Tissue Eng. Regen. Med. 2007, 1:443-449.
133. Oyewumi M.O., Rice K.G. DNA nanoparticle GeneDelivery systems. Nanoparticle Technologyfor Drug Delivery 2006, 361-373. Taylor & Francis Group, New York. R.B. Gupta, U.B. Kompella (Eds.).
134. Pan C.K., Durairaj C., Kompella U.B., Agwu O., Oliver S.C., Quiroz-Mercado H., Mandava N., Olson J.L. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J.Ocul. Pharmacol. Ther. The Off. J. Assoc. Ocul. Pharmacol. Ther. 2011, 27:219-224.
135. Panessa-Warren B.J., Maye M.M., Warren J.B., Crosson K.M. Single walled carbon nanotube reactivity and cytotoxicity following extended aqueous exposure. Environ. Pollut. 2009, 157:1140-1151.
136. Park J.H., Allen M.G., Prausnitz M.R. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J.Control Release 2005, 104:51-66.
137. Park J.H., Allen M.G., Prausnitz M.R. Polymer microneedles for controlled-release drug delivery. Pharm. Res. 2006, 23:1008-1019.
138. Park K., Chen Y., Hu Y., Mayo A.S., Kompella U.B., Longeras R., Ma J.X. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes 2009, 58:1902-1913.
139. Patel S.R., Lin A.S., Edelhauser H.F., Prausnitz M.R. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm. Res. 2011, 28:166-176.
140. Peden M.C., Min J., Meyers C., Lukowski Z., Li Q., Boye S.L., Levine M., Hauswirth W.W., Ratnakaram R., Dawson W., Smith W.C., Sherwood M.B. Ab-externo AAV-mediated gene delivery to the suprachoroidal space using a 250 micron flexible microcatheter. PLoS One 2011, 6:e17140.
141. Pérennès F., Marmiroli B., Matteucci M., Tormen M., Vaccari L., Di Fabrizio E. Sharp beveled tip hollow microneedle arrays fabricated by LIGA and 3D soft lithography with polyvinyl alcohol. J.Micromech. Microeng. 2006, 16:473-479.
142. Peyman G.A., Schulman J.A., Khoobehi B., Alkan H.M., Tawakol M.E., Mani H. Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. Retina 1989, 9:232-236.
143. Pitkanen L., Ranta V.P., Moilanen H., Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest. Ophthalmol. Vis. Sci. 2005, 46:641-646.
144. Pontes de Carvalho R.A., Krausse M.L., Murphree A.L., Schmitt E.E., Campochiaro P.A., Maumenee I.H. Delivery from episcleral exoplants. Invest. Ophthalmol. Vis. Sci. 2006, 47:4532-4539.
145. Prausnitz M.R. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 2004, 56:581-587.
146. Prow T.W., Bhutto I., Kim S.Y., Grebe R., Merges C., McLeod D.S., Uno K., Mennon M., Rodriguez L., Leong K., Lutty G.A. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008, 4:340-349.
147. Qazi Y., Stagg B., Singh N., Singh S., Zhang X., Luo L., Simonis J., Kompella U.B., Ambati B.K. Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 2012, 53:2837-2844.
148. Raghava S., Goel G., Kompella U.B. Ophthalmic applications of nanotechnology. Ocular Transporters in Ophthalmic Diseases and Drug Delivery 2008, 415-436. Humana Press, New Jersey. J. Tombran-Tink, C.J. Barnstable (Eds.).
149. Raghava S., Hammond M., Kompella U.B. Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv. 2004, 1:99-114.
150. Raju H.B., Hu Y., Vedula A., Dubovy S.R., Goldberg J.L. Evaluation of magnetic micro- and nanoparticle toxicity to ocular tissues. PloS One 2011, 6:e17452.
151. Ranta V.P., Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv. Drug Deliv. Rev. 2006, 58:1164-1181.
152. Ruiz-Moreno J.M., Montero J.A., Arias L., Sanabria M.R., Coco R., Silva R., Araiz J., Gomez-Ulla F., Garcia-Layana A. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization. Acta Ophthalmol. Scand. 2006, 84:743-748.
153. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J.Control Release 2010, 145:182-195.
154. Saishin Y., Silva R.L., Saishin Y., Callahan K., Schoch C., Ahlheim M., Lai H., Kane F., Brazzell R.K., Bodmer D., Campochiaro P.A. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest. Ophthalmol. Vis. Sci. 2003, 44:4989-4993.
155. Sakurai E., Ozeki H., Kunou N., Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 2001, 33:31-36.
156. Salazar-Bookaman M.M., Wainer I., Patil P.N. Relevance of drug-melanin interactions to ocular pharmacology and toxicology. J.Ocul. Pharmacol. 1994, 10:217-239.
157. Scheinman R.I., Trivedi R., Vermillion S., Kompella U.B. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine (Lond.) 2011, 6:1669-1682.
158. Schipper M.L., Iyer G., Koh A.L., Cheng Z., Ebenstein Y., Aharoni A., Keren S., Bentolila L.A., Li J., Rao J., Chen X., Banin U., Wu A.M., Sinclair R., Weiss S., Gambhir S.S. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 2009, 5:126-134.
159. Schnitzer J.E., Oh P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J.Biol. Chem. 1994, 269:6072-6082.
160. Schoenwald R.D., Tandon V., Wurster D.E., Barfknecht C.F. Significance of melanin binding and metabolism in the activity of 5-acetoxyacetylimino-4-methyl-delta2-1,3,4,-thiadiazolin e-2-sulfonamide. Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik e.V 1998, 46:39-50.
161. Scholz C. Perspectives on: materials aspects for retinal protheses. J.Bioact Compact Polym. 2010, 22:539-568.
162. Simon B.H., Ando H.Y., Gupta P.K. Circulation time and body distribution of 14C-labeled amino-modified polystyrene nanoparticles in mice. J.Pharm. Sci. 1995, 84:1249-1253.
163. Singh S.R., Grossniklaus H.E., Kang S.J., Edelhauser H.F., Ambati B.K., Kompella U.B. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009, 16:645-659.
164. Steiner K., Buhring K.U., Merck E. The melanin binding of bisoprolol and its toxicological relevance. Lens Eye Tox. Res. 1990, 7:319-333.
165. Stoeber B., Liepmann D. Arrays of hollow out-of-plane micro-needles for drug delivery. J.Microelectromech. Syst. 2005, 14:472-479.
166. Sundaram S., Roy S.K., Ambati B.K., Kompella U.B. Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J. Off. Publ. Fed. Am. Societies Exp. Biol. 2009, 23:3752-3765.
167. Tari S.R., Barile G.R., Kompella U.B. Polychromatic, diversely-sized particles for angiography. A61K 51/00; A61K 49/00; A61K 9/127; A61K 9/14; A61K 9/16 Ed 2009, 19. The Trustees of Columbia University in the City of New York Board or Reagents of the University of Nebraska Varner Hall, United States. Office, U.S.P. (Ed.).
168. Thanou M., Nihot M.T., Jansen M., Verhoef J.C., Junginger H.E. Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia invitro and invivo. J.Pharm. Sci. 2001, 90:38-46.
169. Thanou M., Verhoef J.C., Junginger H.E. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 2001, 50(Suppl. 1):S91-S101.
170. Thanou M., Verhoef J.C., Junginger H.E. Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev. 2001, 52:117-126.
171. Thanou M., Verhoef J.C., Verheijden J.H., Junginger H.E. Intestinal absorption of octreotide using trimethyl chitosan chloride: studies in pigs. Pharm. Res. 2001, 18:823-828.
172. Torchilin V.P. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv. Drug Deliv. Rev. 2002, 54:235-252.
173. Touchard E., Berdugo M., Bigey P., El Sanharawi M., Savoldelli M., Naud M.C., Jeanny J.C., Behar-Cohen F. Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina. Mol. Ther. 2012, 20:1559-1570.
174. Tripathi B.J., Tripathi R.C. Hydrogen peroxide damage to human corneal epithelial cells invitro. Implications for contact lens disinfection systems. Arch. Ophthalmol. 1989, 107:1516-1519.
175. Trivedi R., Kompella U.B. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond.) 2010, 5:485-505.
176. Trivedi R., Tyagi P., Kompella U.B. Deslorelin and Transferrin Mono- and Dual-functionalized Nanomicelles for Tumor Targeted Drug Delivery 2012, American Association of Pharmaceutical Scientists, Chicago, IL.
177. Tsuji A., Tamai I., Sasaki K. Intraocular penetration kinetics of prednisolone after subconjunctival injection in rabbits. Ophthalmic Res. 1988, 20:31-43.
178. Tyagi P., Kadam R.S., Kompella U.B. Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. PLoS One 2012, 7(10):e48188.
179. Tyagi P., Barros M.D., Stansbury J.W., Kompella U.B. Light activated, in situ forming hydrogel for sustained suprachoroidal delivery of a protein drug. 2012 AAPS National Biotechnology Conference, T2014 2012.
180. van der Merwe S.M., Verhoef J.C., Kotze A.F., Junginger H.E. N-trimethyl chitosan chloride as absorption enhancer in oral peptide drug delivery. Dev. characterization minitablet granule formulations. Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik e.V 2004, 57:85-91.
181. van der Merwe S.M., Verhoef J.C., Verheijden J.H., Kotze A.F., Junginger H.E. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik e.V 2004, 58:225-235.
182. Van Quill K.R., Dioguardi P.K., Tong C.T., Gilbert J.A., Aaberg T.M., Grossniklaus H.E., Edelhauser H.F., O'Brien J.M. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 2005, 112:1151-1158.
183. Verbaan F.J., Bal S.M., van den Berg D.J., Dijksman J.A., van Hecke M., Verpoorten H., van den Berg A., Luttge R., Bouwstra J.A. Improved piercing of microneedle arrays in dermatomed human skin by an impact insertion method. J.Control Release 2008, 128:80-88.
184. Veritti D., Lanzetta P., Perissin L., Bandello F. Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up. Invest. Ophthalmol. Vis. Sci. 2009, 50:2391-2397.
185. Vinogradov S.V., Batrakova E.V., Kabanov A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem. 2004, 15:50-60.
186. Vogel S.M., Minshall R.D., Pilipovic M., Tiruppathi C., Malik A.B. Albumin uptake and transcytosis in endothelial cells invivo induced by albumin-binding protein. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:L1512-L1522.
187. Wang J., Lu J., Ly S.Y., Vuki M., Tian B., Adeniyi W.K., Armendariz R.A. Lab-on-a-Cable for electrochemical monitoring of phenolic contaminants. Anal. Chem. 2000, 72:2659-2663.
188. Weijtens O., Feron E.J., Schoemaker R.C., Cohen A.F., Lentjes E.G., Romijn F.P., van Meurs J.C. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am. J. Ophthalmol. 1999, 128:192-197.
189. Weijtens O., Schoemaker R.C., Cohen A.F., Romijn F.P., Lentjes E.G., van Rooij J., van Meurs J.C. Dexamethasone concentration in vitreous and serum after oral administration. Am. J. Ophthalmol. 1998, 125:673-679.
190. Weijtens O., Schoemaker R.C., Lentjes E.G., Romijn F.P., Cohen A.F., van Meurs J.C. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology 2000, 107:1932-1938.
191. Weijtens O., van der Sluijs F.A., Schoemaker R.C., Lentjes E.G., Cohen A.F., Romijn F.P., van Meurs J.C. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am. J. Ophthalmol. 1997, 123:358-363.
192. Wilson D.F., Vinogradov S.A., Grosul P., Vaccarezza M.N., Kuroki A., Bennett J. Oxygen distribution and vascular injury in the mouse eye measured by phosphorescence-lifetime imaging. Appl. Opt. 2005, 44:5239-5248.
193. Yang H., Tyagi P., Kadam R.S., Holden C.A., Kompella U.B. AHybrid Dendrimer Hydrogel/PLGA Nanoparticle Platform Sustains Drug Delivery for One Week and Antiglaucoma Effects for Four Days Following One-time Topical Administration 2012, ACS Nano.
194. Yang M., Zahn J.D. Microneedle insertion force reduction using vibratory actuation. Biomed. Microdevices 2004, 6:177-182.
195. Young S., Larkin G., Branley M., Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin. Exp. Ophthalmol. 2001, 29:2-6.
196. Zhang P., Summer W.R., Bagby G.J., Nelson S. Innate immunity and pulmonary host defense. Immunol. Rev. 2000, 173:39-51.
197. Zolnik B.S., Gonzalez-Fernandez A., Sadrieh N., Dobrovolskaia M.A. Nanoparticles and the immune system. Endocrinology 2010, 151:458-465.